CORRGENE
CorrGene is an innovative company focusing on the research and development and production of new anti-cancer drugs and rare diseases with gene editing technology and cell therapy. The company was established by a group of cell and gene therapy experts, virologists, oncologists, hematologists and biopharmaceutical industry veterans. CorrGene was established in January, 2022 in Jiangsu, China.
CORRGENE
Industry:
Biotechnology Health Care Medical
Founded:
2022-01-01
Address:
Nanjing, Jiangsu, China
Country:
China
Status:
Active
Total Funding:
15.7 M USD
Investors List
Wuxi Capital
Wuxi Capital investment in Seed Round - CorrGene
Med-Fine Capital
Med-Fine Capital investment in Seed Round - CorrGene
Golden Capital Partners
Golden Capital Partners investment in Seed Round - CorrGene
More informations about "CorrGene"
CorrGene Company Profile 2024: Valuation, Funding & Investors
CorrGene General Information Description. Researcher and developer of rare disease cell therapy. The company utilizes gene editing technology in developing new drugs for cancer and …See details»
CorrGene - Funding, Financials, Valuation & Investors - Crunchbase
How much funding has this organization raised over time? Show . Announced Date . Transaction Name . Number of Investors . Money Raised . Lead Investors . Feb 28, 2022: Seed Round - …See details»
corregene - Products, Competitors, Financials, Employees, …
Headquarters Location. Building 1, Bohui Innovation Building, No. 9 Shengshengyuan Road, Changping District . Beijing, Beijing, 102206, China. 86-10-86464526See details»
CorrGene Biotechnology Co., Ltd.: Drug pipelines, Patents, Clinical ...
Explore CorrGene Biotechnology Co., Ltd. with its drug pipeline, therapeutic area, technology platform, 1 news, Disease Domain:Hemic and Lymphatic Diseases, Endocrinology and …See details»
CorreGene
Founded by several alumni of Peking University, Beijing CorreGene Biotechnology Co., Ltd. is dedicated to the development of innovative therapeutics based on T-cell …See details»
CorreGene Company Profile 2025: Valuation, Funding & Investors
CorreGene General Information Description. Developer of gene biotechnology designed for anti-tumor immunotherapy. The company has established an internationally leading SMART-TCR …See details»
CorrDan Trademark of CorrGene Biotechnology Co., Ltd.
CorrDan is a trademark and brand of CorrGene Biotechnology Co., Ltd., Wuxi City, Jiangsu Province, CHINA. This trademark was filed to EUIPO on Thursday, March 31, 2022. The …See details»
Company Profile - CorreGene
Rewarded as Technology Research and Development Organization in Changping District. 2022.11. Rewarded as Beijing Postdoctoral Innovation Research Center 2021.04. KRAS …See details»
Corrgene Biotechnology Co. Ltd.: Drug pipelines, Patents, Clinical ...
Dec 17, 2023 Explore Corrgene Biotechnology Co. Ltd. with its drug pipeline, therapeutic area, technology platform, .See details»
CorrGene - Updates, News, Events, Signals & Triggers - Crunchbase
CorrGene is a researcher and developer of rare disease cell therapy.See details»
CorrGene: Drug pipelines, Patents, Clinical trials - Synapse
Jul 4, 2023 Explore CorrGene with its drug pipeline, therapeutic area, technology platform, .See details»
CorrGene - Crunchbase
Companies like CorrGene include Verismo Therapeutics, Structure Therapeutics, and Prolocor. Prolocor Philadelphia , Pennsylvania , United States 3 Contacts 1-10 employeesSee details»
(@corrgene) • Instagram photos and videos
0 Followers, 304 Following, 9 Posts - See Instagram photos and videos from (@corrgene)See details»
Epidermolysis Bullosa(CorrGene Biotechnology) - Drug Targets
Epidermolysis Bullosa(CorrGene Biotechnology), Initially developed by Wuxi Kejin Biotechnology Co., Ltd., Now, its global highest R&D status is Preclinical, Therapeutic Areas: Congenital …See details»
CorreGene and EurekaBio Enter into Strategic Partnership to …
On December 30, 2022, Beijing CorreGene Biotechnology Co., Ltd (hereinafter referred to as “CorreGene”) and Shenzhen Eureka Biotechnology Co., Ltd. (hereinafter referred to as …See details»
Seed Round - CorrGene - 2022-02-28 - Crunchbase
Feb 28, 2022 Organization Name . CorrGene . Announced Date Feb 28, 2022; Funding Type ...See details»
CG-001(CorrGene) - Drug Targets, Indications, Patents - Synapse
Nov 21, 2024 Autologous CD34+ cells edited with CRISPR/Cas9 and transduced with an adeno-associated virus vector serotype 6 containing the codon-optimized version of PKLR gene, …See details»
17 Yarn Storage Ideas (How To Store Your Stash) - Handy Little Me
1 day ago Minimalist Yarn Storage & Organization by Heather Corinne Crochets Photo Credit: www.heather-corinne.com In this blog post, you will see Heather Corinne's approach to …See details»
Wisckott-Aldrich Syndrome(CorrGene Biotechnology) - Drug …
Wisckott-Aldrich Syndrome(CorrGene Biotechnology), Initially developed by Wuxi Kejin Biotechnology Co., Ltd., Now, its global highest R&D status is Preclinical, Therapeutic Areas: …See details»
Primary Hyperoxaluria T.1(CorrGene Biotechnology) - Drug Targets ...
Primary Hyperoxaluria T.1(CorrGene Biotechnology), Initially developed by Wuxi Kejin Biotechnology Co., Ltd., Now, its global highest R&D status is Preclinical, Therapeutic Areas: …See details»